Application of Nanobiotechnology in Cancer Therapeutics

  • K. K. Jain

Nanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale, i.e., at the level of atoms, molecules, and supramolecular structures. Nanotechnology, as defined by the National Nanotechnology Initiative (, is the understanding and control of matter at dimensions of roughly 1–100 nm, where unique phenomena enable novel applications. During the past few years, considerable progress has been made in the application of nanobiotechnology in cancer, i.e. nanooncology, which is currently the most important chapter of nanomedicine [1,2]. Other publications have covered applications of nanobiotechnology in diagnostics [3], drug discovery [4], and drug delivery [5]. Several drugs in development for cancer are based on nanotechnology and a few of these are already approved. Nanotechnology-based devices are in development as aids to cancer surgery. Some of the recent development in nanotechnologies and their applications in diagnosing and developing cancer therapies are reviewed in this chapter. The impact of nanobiotechnology on oncology is shown schematically in Fig. 1.


Drug Delivery Sentinel Lymph Node Silver Nanoparticles Iron Oxide Nanoparticles Polymeric Micelle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jain KK. A Handbook of Nanomedicine. Humana/Springer, Totowa, NJ, 2008.Google Scholar
  2. 2.
    Jain KK. Recent Advances in Nanooncology. Technol Cancer Res Treat 2008; 7: 1–13.PubMedGoogle Scholar
  3. 3.
    Jain KK. Applications of Nanobiotechnology in Clinical Diagnostics. Clin Chem 2007; 53: 2002–2009.PubMedCrossRefGoogle Scholar
  4. 4.
    Jain KK. Role of nanobiotechnology in drug discovery. In: Guzman CA, Feuerstein G (eds) Pharmaceutical Biotechnology. Austin, TX, Landes Press, 2009.Google Scholar
  5. 5.
    Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 2005; 4: 407–416.PubMedGoogle Scholar
  6. 6.
    Jain KK. Cancer Biomarkers: Current issues and future directions. Curr Opin Mol Ther 2007; 9: 563–571.PubMedGoogle Scholar
  7. 7.
    Zheng G, Patolsky F, Cui Y, et al. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 2005; 23: 1294–1301.PubMedCrossRefGoogle Scholar
  8. 8.
    Singer EM, Smith SS. Nucleoprotein Assemblies for Cellular Biomarker Detection. Nano Lett 2006; 6: 1184–1189.PubMedCrossRefGoogle Scholar
  9. 9.
    Jain KK. Nanobiotechnology: Applications, Markets and Companies. Basel, Jain PharmaBiotech, 2009.Google Scholar
  10. 10.
    Zharov VP, Galitovskaya EN, Johnson C, Kelly T. Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: Potential for cancer therapy. Lasers Surg Med 2005; 37: 219–226.PubMedCrossRefGoogle Scholar
  11. 11.
    Li J, Wang X, Wang C, et al. The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem 2007; 2: 374–378.PubMedCrossRefGoogle Scholar
  12. 12.
    Jain PK, Huang X, El-Sayed IH, El-Sayed MA. Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc Chem Res 2008c May 1; doi:10.1021/ar7002804.Google Scholar
  13. 13.
    Wu Q, Cao H, Luan Q, et al. Biomolecule-assisted synthesis of water-soluble silver nanoparticles and their biomedical applications. Inorg Chem 2008; 47: 5882–5888.Google Scholar
  14. 14.
    Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum Dot-Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer. Nano Lett 2007; 7: 3065–3070.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu X, Munge B, Patel V, et al. Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc 2006; 128: 11199–11205.PubMedCrossRefGoogle Scholar
  16. 16.
    Bianco A, Kostarelos K, Prato M. Opportunities and challenges of carbon-based nanomaterials for cancer therapy. Expert Opin Drug Deliv 2008; 5: 331–342.PubMedCrossRefGoogle Scholar
  17. 17.
    Hampel S, Kunze D, Haase D, et al. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine 2008; 3: 175–182.PubMedCrossRefGoogle Scholar
  18. 18.
    Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12: 6677–6686.PubMedCrossRefGoogle Scholar
  19. 19.
    Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci 2007; 104: 932–936.PubMedCrossRefGoogle Scholar
  20. 20.
    Rabin O, Manuel Perez J, Grimm J. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006; 5: 118–122.PubMedCrossRefGoogle Scholar
  21. 21.
    Gao D, Xu H, Philbert MA, et al. Ultrafine Hydrogel Nanoparticles: Synthetic Approach and Therapeutic Application in Living Cells. Angew Chem Int Ed Engl 2007; 46: 2224–2227.PubMedCrossRefGoogle Scholar
  22. 22.
    Choi J, Jun Y, Yeon S, et al. Biocompatible Heterostructured Nanoparticles for Multimodal Biological Detection. JACS 2006; 128: 5982–15983.Google Scholar
  23. 23.
    Talanov VS, Regino CA, Kobayashi H, et al. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett 2006; 6: 1459–1463.PubMedCrossRefGoogle Scholar
  24. 24.
    Koster DA, Palle K, Bot ES, et al. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007; 448: 213–217.PubMedCrossRefGoogle Scholar
  25. 25.
    Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56: 303–317.PubMedCrossRefGoogle Scholar
  26. 26.
    Gao X, Dave SR. Quantum dots for cancer molecular imaging. Adv Exp Med Biol 2007; 620: 57–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Koo OM, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid nano-micelles: A novel solvent pH change solubilization method. J Nanosci Nanotechnol 2006; 6: 2996–3000.PubMedCrossRefGoogle Scholar
  28. 28.
    Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotech 2007; 2: 249–255.CrossRefGoogle Scholar
  29. 29.
    Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized Micellar Systems for Cancer Targeted Drug Delivery. Pharmaceutical Res 2007; 24: 1029–1046.CrossRefGoogle Scholar
  30. 30.
    Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007; 3: 1341–1346.PubMedCrossRefGoogle Scholar
  31. 31.
    MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics. Cancer Cell 2007; 11: 431–445.PubMedCrossRefGoogle Scholar
  32. 32.
    Wagner E. Programmed drug delivery: Nanosystems for tumor targeting. Expert Opin Biol Ther 2007; 7: 587–593.PubMedCrossRefGoogle Scholar
  33. 33.
    Radosz M, Shen Y, Tang H. Nanoparticles for Cytoplasmic Drug Delivery to Cancer Cells. Patent #WO/2007/001356, Publication Date 4 January 2007.Google Scholar
  34. 34.
    Lee CC, Gillies ER, Fox ME. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci 2006; 103: 16649–16654.PubMedCrossRefGoogle Scholar
  35. 35.
    McDevitt MR, Chattopadhyay D, Kappel BJ, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48: 1180–1189.PubMedCrossRefGoogle Scholar
  36. 36.
    Ashcroft JM, Tsyboulski DA, Hartman KB, et al. Fullerene (C60) immunoconjugates: Interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun 2006; 28: 3004–3006.CrossRefGoogle Scholar
  37. 37.
    Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-{beta} signaling. Proc Natl Acad Sci 2007; 104: 3460–3465.PubMedCrossRefGoogle Scholar
  38. 38.
    Qian X, Peng XH, Ansari DO, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotech 2008; 26: 83–90.CrossRefGoogle Scholar
  39. 39.
    Jia N, Lian Q, Shen H, et al. Intracellular delivery of quantum dots tagged antisense oligodeoxynucleotides by functionalized multiwalled carbon nanotubes. Nano Lett 2007; 7: 2976–2980.PubMedCrossRefGoogle Scholar
  40. 40.
    Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68: 6652–6660.PubMedCrossRefGoogle Scholar
  41. 41.
    Murakami T, Sawada H, Tamura G, et al. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomed 2008; 3: 453–463.CrossRefGoogle Scholar
  42. 42.
    Ahmed F, Pakunlu RI, Srinivas G, et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm 2006; 3: 340–350.PubMedCrossRefGoogle Scholar
  43. 43.
    Bertin PA, Gibbs JM, Shen CK, et al. Multifunctional polymeric nanoparticles from diverse bioactive agents. J Am Chem Soc 2006; 128: 4168–4169.PubMedCrossRefGoogle Scholar
  44. 44.
    Peng W, Anderson DG, Bao Y, et al. Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors. Prostate 2007; 67: 855–862.PubMedCrossRefGoogle Scholar
  45. 45.
    Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 2007; 7: 363–372.PubMedCrossRefGoogle Scholar
  46. 46.
    van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007; 67: 4843–4850.PubMedCrossRefGoogle Scholar
  47. 47.
    Cinteza LO, Ohulchanskyy TY, Sahoo Y, et al. Diacyllipid Micelle-Based Nanocarrier for Magnetically Guided Delivery of Drugs in Photodynamic Therapy. Mol Pharm 2006; 3: 415–423.PubMedCrossRefGoogle Scholar
  48. 48.
    Ohulchanskyy TY, Roy I, Goswami LN, Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett 2007; 7: 2835–2842.PubMedCrossRefGoogle Scholar
  49. 49.
    Rapoport N, Gao Z, Kennedy A. Multifunctional Nanoparticles for Combining Ultrasonic Tumor Imaging and Targeted Chemotherapy. J Natl Cancer Inst 2007; 99: 1095–1106.PubMedCrossRefGoogle Scholar
  50. 50.
    Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: Feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007; 52: 1653–1661.PubMedCrossRefGoogle Scholar
  51. 51.
    Lehmann J, Natarajan A, Denardo GL, et al. Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. Cancer Biother Radiopharm 2008; 23: 265–271.PubMedCrossRefGoogle Scholar
  52. 52.
    Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006; 128: 2115–2120.PubMedCrossRefGoogle Scholar
  53. 53.
    Everts M. Thermal scalpel to target cancer. Expert Rev Med Devices 2007; 4: 131–136.PubMedCrossRefGoogle Scholar
  54. 54.
    Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35: 61–67.PubMedCrossRefGoogle Scholar
  55. 55.
    Robe A, Pic E, Lassalle HP, et al. Quantum dots in axillary lymph node mapping: Biodistribution study in healthy mice. BMC Cancer 2008; 8: 111.PubMedCrossRefGoogle Scholar
  56. 56.
    Wang P, Jia L, Sanders BG, Kline K. Liposomal or nanoparticle alpha-TEA reduced 66 cl-4 murine mammary cancer burden and metastasis. Drug Deliv 2007; 14: 497–505.PubMedCrossRefGoogle Scholar
  57. 57.
    Gordon EM, Levy JP, Reed RA, et al. Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol 2008; 33: 665–675.PubMedGoogle Scholar
  58. 58.
    Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 2005; 4: 645–650.PubMedGoogle Scholar
  59. 59.
    Takeda M, Tada H, Higuchi H, et al. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Breast Cancer 2008; 15: 145–152.PubMedCrossRefGoogle Scholar
  60. 60.
    Sakamoto J, Annapragada A, Decuzzi P, Ferrari M. Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv 2007; 4: 359–369.PubMedCrossRefGoogle Scholar
  61. 61.
    Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology Applications in Cancer. Annu Rev Biomed Eng 2007; 9: 12.1–12.32.CrossRefGoogle Scholar
  62. 62.
    Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: Biological and clinical perspectives. Nanomedicine 2008; 3: 83–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechSwitzerland

Personalised recommendations